HINDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Vyome Holdings, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.84−0.03 (-1.60%)
Close on Oct 19, 2026
- Market cap
- $12.91M
- P/E (TTM)
- –
- Dividend yield
- –
Vyome Holdings, Inc revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical [Member] | $319.71K | $256.94K | – | – | – | – | 100.0% | +24.4% |
| Single reportable segment | – | $8.01M | $8.68M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Sale of products [Member] | $174.65K | $134.40K | – | – | – | – | 54.6% | +29.9% |
| Licensing and milestone fees Luliconazole [Member] | $116.90K | – | – | – | – | – | 36.6% | – |
| Royalty income related to above product sales [Member] | $28.17K | $47.40K | – | – | – | – | 8.8% | -40.6% |
| Reshape vest and diabetes bloc-stim neuromodulation products | – | – | – | – | $0 | $0 | – | – |
| DBSN Device | – | – | $0 | $0 | $0 | – | – | – |
| Service fee for arrangements for sale of Dandruff products [Member] | – | $75.15K | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| United States | – | $6.89M | $7.13M | $9.23M | $10.30M | $8.28M | – | – |
| Australia | – | $392.00K | $526.00K | $688.00K | $1.04M | $1.09M | – | – |
| Europe | – | $687.00K | $956.00K | $1.25M | $2.13M | $1.82M | – | – |
| Rest of world | – | $40.00K | $62.00K | $70.00K | $137.00K | $114.00K | – | – |
From the segment and revenue-disaggregation notes of Vyome's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.